Physician profile
Cullen M Dutmer
NPI 1972823524
$28,018.32
in general payments reported to CMS, 2019-2025
10 companies · $12K in 2025
The $12K reported for 2025 was more than what 87% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2021: $1,620 · 2022: $191 · 2023: $227 · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $2,598 · Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,362.50 |
| Travel and Lodging | $2,598.15 |
| Food and Beverage | $2,057.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,547.48 | 2024-2025 | Actimmune |
| Novartis Pharmaceuticals Corporation | $6,033.20 | 2025 | |
| Pharming Healthcare, INC. | $3,265.90 | 2024-2025 | Joenja, Ruconest |
| Horizon Therapeutics Plc | $1,620.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $795.33 | 2022-2025 | Fasenra |
| Grifols USA, LLC | $401.43 | 2023-2025 | Xembify |
| Grifols Shared Services North America, INC. | $139.46 | 2023-2025 | Xembify |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Glaxosmithkline, LLC. | $64.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.97 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cullen Dutmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.